Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); Focus on New CK357 ALS Phase 2 Data at AAN in April
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $72.03 +1.58%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Cytokinetics (NASDAQ: CYTK) price target of $6.00.
Analyst, Ritu Baral, said, "We see CYTK shares as inexpensive on potential of CK357 in ALS, AMGN- K357 in ALS, AMGN---partnered omecamtiv in heart failure. We think CK357 Phase 1/2 proof-of-concept data in ALS shows great efficacy potential despite a noisy side-effect profile. We also think partner Amgen (Nasdaq: AMGN) is committed to the development of omecamtiv for heart failure."
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $1.08 yesterday.
Analyst, Ritu Baral, said, "We see CYTK shares as inexpensive on potential of CK357 in ALS, AMGN- K357 in ALS, AMGN---partnered omecamtiv in heart failure. We think CK357 Phase 1/2 proof-of-concept data in ALS shows great efficacy potential despite a noisy side-effect profile. We also think partner Amgen (Nasdaq: AMGN) is committed to the development of omecamtiv for heart failure."
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $1.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Callaway Golf (CALY) PT Raised to $20 at Truist Securities
- salesforce.com (CRM) PT Raised to $300 at TD Cowen
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
